The estimated Net Worth of Keith Lamont Cummings is at least $4.56 Million dollars as of 10 July 2024. Dr Cummings owns over 10,911 units of Pliant Therapeutics stock worth over $3,458,730 and over the last 4 years he sold PLRX stock worth over $1,099,054.
Dr has made over 15 trades of the Pliant Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 10,911 units of PLRX stock worth $126,131 on 10 July 2024.
The largest trade he's ever made was exercising 30,750 units of Pliant Therapeutics stock on 13 June 2023 worth over $63,960. On average, Dr trades about 10,643 units every 68 days since 2020. As of 10 July 2024 he still owns at least 282,115 units of Pliant Therapeutics stock.
You can see the complete history of Dr Cummings stock trades at the bottom of the page.
Dr. Keith Lamont Cummings M.B.A., M.D. is the Chief Financial Officer at Pliant Therapeutics.
Dr D is 44, he's been the Chief Financial Officer of Pliant Therapeutics since . There are 4 older and no younger executives at Pliant Therapeutics. The oldest executive at Pliant Therapeutics, Inc. is Dr. Ãric Lefebvre M.D., 57, who is the Chief Medical Officer.
Keith's mailing address filed with the SEC is C/O PLIANT THERAPEUTICS, INC., 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 4 years, insiders at Pliant Therapeutics have traded over $16,925,448 worth of Pliant Therapeutics stock. The most active insiders traders include Group, Llc Green Jeremy Red..., Rock Ventures Iii, L.P.Thir..., and Thomas A Mccourt. On average, Pliant Therapeutics executives and independent directors trade stock every 24 days with the average trade being worth of $221,612. The most recent stock trade was executed by Eric Lefebvre on 10 July 2024, trading 12,319 units of PLRX stock currently worth $142,408.
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Pliant Therapeutics executives and other stock owners filed with the SEC include: